CardioDynamics Reports Third Quarter 2008 Results, Seventh Consecutive Quarterly Revenue Growth and 15% Year to Date Revenu...() Statement Except for historical and...)

Except for historical and factual information contained herein, this press release contains forward-looking statements, such as revenue growth rates and cash flow projections, operating performance and acceptance of ICG technology, the accuracy of which is necessarily subject to uncertainties and risks, including the Company's ability to meet its short and long-term liquidity and capital needs, primary dependence on the BioZ(R) product line, and various uncertainties characteristic of early stage companies, as well as other risks detailed in the Company's filings with the SEC, including its 2007 Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Future events and actual results could differ materially from the forward-looking statements. Readers are urged not to place undue reliance on forward-looking statements. The Company does not undertake to update the disclosures contained in this press release.

CardioDynamics International Corporation

In thousands, except per share data (unaudited)

Selected Consolidated Operational Three Months Nine Months

Results Ended Ended

August 31, August 31,

2008 2007 2008 2007

Net sales $6,066 $5,591 $18,008 $15,699

Cost of sales 1,519 1,554 5,066 4,740

Gross margin 4,547 4,037 12,942 10,959

Research and development 386 420 1,070 1,317

Selling and marketing 3,669 3,977 11,112 11,101

General and administrative 714 772 2,246 2,437

Amortization of intangible assets 32 30 96 115

Loss from operations (2
'/>"/>